Rb family proteins in gastric cancer (review)

Oncology Reports

Volumn 24, Issue 6, 2010, Pages 1411-1418

  Cito, Letizia ^a   Pentimalli, Francesca ^a,c   Forte, Iris ^a,b   Mattioli, Eliseo ^b   Giordano, Antonio ^a,c  

^a CROM Center of Oncology Research Mercogliano   (Italy)

^b UNIVERSITY OF SIENA   (Italy)

^c TEMPLE UNIVERSITY   (United States)

Author keywords

Gastric cancer; Rb family proteins

Indexed keywords

PROTEIN P105; PROTEIN P107; PROTEIN P130; RETINOBLASTOMA PROTEIN; UVOMORULIN;

ARTICLE; CANCER CELL CULTURE; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL CYCLE PROGRESSION; CELL CYCLE REGULATION; CELL CYCLE S PHASE; GASTROINTESTINAL TUMOR; HELICOBACTER PYLORI; HUMAN; MUTATION; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN FAMILY; STOMACH CANCER;

ANIMALS; CARCINOMA; DISEASE PROGRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MULTIGENE FAMILY; PROGNOSIS; RETINOBLASTOMA PROTEIN; STOMACH NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 78649417608     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or-00001000     Document Type: Article

References (132)

1. Aragones N, Pollan M, Rodero I and Lopez-Abente G: Gastric cancer in the European Union (1968-1992): mortality trends and cohort effect. Ann Epidemiol 7: 294-303, 1997.
2. Levi F, Lucchini F, Negri E and La Vecchia C: Trends in mortality from major cancers in the European Union, including acceding countries, in 2004. Cancer 101: 2843-2850, 2004.
3. Garcia-Esquinas E, Perez-Gomez B, Pollan M, Boldo E, Fernandez-Navarro P, Lope V, Vidal E, Lopez-Abente G and Aragones N: Gastric cancer mortality trends in Spain, 1976- 2005, differences by autonomous region and sex. BMC Cancer 9: 346, 2009.
4. Mousavi SM and Somi MH: Gastric cancer in Iran 1966-2006. Asian Pac J Cancer Prev 10: 407-412, 2009.
5. Kaneko S and Yoshimura T: Time trend analysis of gastric cancer incidence in Japan by histological types, 1975-1989. Br J Cancer 84: 400-405, 2001.
6. Kim JI, Kim SG, Kim N, Kim JG, Shin SJ, Kim SW, Kim HS, Sung JK, Yang CH, Shim KN, Park SJ, Park JY, Baik GH, Lee SW, Park JJ, Hong SJ, Lee GH, Seo GS, Lee SI and Jung HC: Changing prevalence of upper gastrointestinal disease in 28893 Koreans from 1995 to 2005. Eur J Gastroenterol Hepatol 21: 787-793, 2009.
7. Lee JY, Kim HY, Kim KH, Jang HJ, Kim JB, Lee JH, Kim DJ, Kim YB, Kim WJ and Yoo JY: No changing trends in incidence of gastric cardia cancer in Korea. J Korean Med Sci 18: 53-57, 2003.
8. Lauren P: The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma. An attempt at a histoclinical classification. Acta Pathol Microbiol Scand 64: 31-49, 1965.
9. Stelzner S and Emmrich P: The mixed type in Lauren's classification of gastric carcinoma. Histologic description and biologic behavior. Gen Diagn Pathol 143: 39-48, 1997.
10. Key TJ, Appleby PN, Spencer EA, Travis RC, Allen NE, Thorogood M and Mann JI: Cancer incidence in British vegetarians. Br J Cancer 101: 192-197, 2009.
11. Liu C and Russell RM: Nutrition and gastric cancer risk: an update. Nutr Rev 66: 237-249, 2007.
12. Jakszyn P and Gonzalez CA: Nitrosamine and related food intake and gastric and oesophageal cancer risk: a systematic review of the epidemiological evidence. World J Gastroenterol 12: 4296-4303, 2006. (Pubitemid 44194520)
13. Strumylaite L, Zickute J, Dudzevicius J and Dregval L: Saltpreserved foods and risk of gastric cancer. Medicina (Kaunas) 42: 164-170, 2006.
14. McCullough ML, Robertson AS, Jacobs EJ, Chao A, Calle EE and Thun MJ: A prospective study of diet and stomach cancer mortality in United States men and women. Cancer Epidemiol Biomarkers Prev 10: 1201-1205, 2001.
15. Coleman MP, Esteve J, Damiecki P, Arslan A and Renard H: Trends in cancer incidence and mortality. IARC Sci Publ pp1-806, 1993.
16. Maskarinec G and Noh JJ: The effect of migration on cancer incidence among Japanese in Hawaii. Ethn Dis 14: 431-439, 2004.
17. Li H, Kalies I, Mellgard B and Helander HF: A rat model of chronic Helicobacter pylori infection: studies of epithelial cell turnover and gastric ulcer healing. Scand J Gastroenterol 33: 370-378, 1998.
18. Nardone G, Staibano S, Rocco A, Mezza E, D'Armiento FP, Insabato L, Coppola A, Salvatore G, Lucariello A, Figura N, De Rosa G and Budillon G: Effect of Helicobacter pylori infection and its eradication on cell proliferation, DNA status, and oncogene expression in patients with chronic gastritis. Gut 44: 789-799, 1999.
19. Danesh J: Helicobacter pylori infection and gastric cancer: systematic review of the epidemiological studies. Aliment Pharmacol Ther 13: 851-856, 1999.
20. Uemura N, Okamoto S, Yamamoto S, Matsumura N, Yamaguchi S, Yamakido M, Taniyama K, Sasaki N and Schlemper RJ: Helicobacter pylori infection and the development of gastric cancer. N Engl J Med 345: 784-789, 2001.
21. Guilford P, Hopkins J, Harraway J, McLeod M, McLeod N, Harawira P, Taite H, Scoular R, Miller A and Reeve AE: E-cadherin germline mutations in familial gastric cancer. Nature 392: 402-405, 1998.
22. Suriano G, Yew S, Ferreira P, Senz J, Kaurah P, Ford JM, Longacre TA, Norton JA, Chun N, Young S, Oliveira MJ, Macgillivray B, Rao A, Sears D, Jackson CE, Boyd J, Yee C, Deters C, Pai GS, Hammond LS, McGivern BJ, Medgyesy D, Sartz D, Arun B, Oelschlager BK, Upton MP, Neufeld-Kaiser W, Silva OE, Donenberg TR, Kooby DA, Sharma S, Jonsson BA, Gronberg H, Gallinger S, Seruca R, Lynch H and Huntsman DG: Characterization of a recurrent germ line mutation of the E-cadherin gene: implications for genetic testing and clinical management. Clin Cancer Res 11: 5401-5409, 2005.
23. Kaurah P, MacMillan A, Boyd N, Senz J, De Luca A, Chun N, Suriano G, Zaor S, Van Manen L, Gilpin C, Nikkel S, Connolly-Wilson M, Weissman S, Rubinstein WS, Sebold C, Greenstein R, Stroop J, Yim D, Panzini B, McKinnon W, Greenblatt 24. M, Wirtzfeld D, Fontaine D, Coit D, Yoon S, Chung D, Lauwers G, Pizzuti A, Vaccaro C, Redal MA, Oliveira C, Tischkowitz M, Olschwang S, Gallinger S, Lynch H, Green J, Ford J, Pharoah P, Fernandez B and Huntsman D: Founder and recurrent CDH1 mutations in families with hereditary diffuse gastric cancer. JAMA 297: 2360-2372, 2007.
24. Graziano F, Arduini F, Ruzzo A, Bearzi I, Humar B, More H, Silva R, Muretto P, Guilford P, Testa E, Mari D, Magnani M and Cascinu S: Prognostic analysis of E-cadherin gene promoter hypermethylation in patients with surgically resected, node-positive, diffuse gastric cancer. Clin Cancer Res 10: 2784-2789, 2005.
25. Waki T, Tamura G, Sato M, Terashima M, Nishizuka S and Motoyama T: Promoter methylation status of DAP-kinase and RUNX3 genes in neoplastic and non-neoplastic gastric epithelia. Cancer Sci 94: 360-364, 2004.
26. Ito K, Liu Q, Salto-Tellez M, Yano T, Tada K, Ida H, Huang C, Shah N, Inoue M, Rajnakova A, Hiong KC, Peh BK, Han HC, Ito T, Teh M, Yeoh KG and Ito Y: RUNX3, a novel tumor suppressor, is frequently inactivated in gastric cancer by protein mislocalization. Cancer Res 65: 7743-7750, 2005.
27. Li QL, Ito K, Sakakura C, Fukamachi H, Inoue K, Chi XZ, Lee KY, Nomura S, Lee CW, Han SB, Kim HM, Kim WJ, Yamamoto H, Yamashita N, Yano T, Ikeda T, Itohara S, Inazawa J, Abe T, Hagiwara A, Yamagishi H, Ooe A, Kaneda A, Sugimura T, Ushijima T, Bae SC and Ito Y: Causal relationship between the loss of RUNX3 expression and gastric cancer. Cell 109: 113-124, 2002.
28. Weinberg RA: The molecular basis of oncogenes and tumor suppressor genes. Ann N Y Acad Sci 758: 331-338, 1995.
29. Strong LC, Riccardi VM, Ferrell RE and Sparkes RS: Familial retinoblastoma and chromosome 13 deletion transmitted via an insertional translocation. Science 213: 1501-1503, 1981.
30. Baldi A, De Luca A, Claudio PP, Baldi F, Giordano GG, Tommasino M, Paggi MG and Giordano A: The RB2/p130 gene product is a nuclear protein whose phosphorylation is cell cycle regulated. J Cell Biochem 59: 402-408, 1995.
31. Zhu L, van den Heuvel S, Helin K, Fattaey A, Ewen M, Livingston D, Dyson N and Harlow E: Inhibition of cell proliferation by p107, a relative of the retinoblastoma protein. Genes Dev 7: 1111-1125, 1993. (Pubitemid 23207404)
32. Ferreira R, Magnaghi-Jaulin L, Robin P, Harel-Bellan A and Trouche D: The three members of the pocket proteins family share the ability to repress E2F activity through recruitment of a histone deacetylase. Proc Natl Acad Sci USA 95: 10493-10498, 1998.
33. Sardet C, Vidal M, Cobrinik D, Geng Y, Onufryk C, Chen A and Weinberg RA: E2f-4 and e2f-5, two members of the e2f family, are expressed in the early phases of the cell cycle. Proc Natl Acad Sci USA 92: 2403-2407, 1995.
34. Kim J, Bhinge AA, Morgan XC and Iyer VR: Mapping DNA-protein interactions in large genomes by sequence tag analysis of genomic enrichment. Nat Methods 2: 47-53, 2005.
35. Takahashi Y, Rayman JB and Dynlacht BD: Analysis of promoter binding by the E2F and pRB families in vivo: distinct E2F proteins mediate activation and repression. Genes Dev 14: 804-816, 2000.
36. Ren B, Cam H, Takahashi Y, Volkert T, Terragni J, Young RA and Dynlacht BD: E2F integrates cell cycle progression with DNA repair, replication, and G(2)/M checkpoints. Genes Dev 16: 245-256, 2002.
37. Hitomi M and Stacey DW: Cyclin D1 production in cycling cells depends on ras in a cell-cycle-specific manner. Curr Biol 9: 1075-1084, 1999. (Pubitemid 29504477)
38. Pentimalli F, Cito L and Giordano A: Dysfunction of the RB retinoblastoma gene in cancer. In: Checkpoint Controls and Targets in Cancer Therapy. Siddik ZH (ed.) Humana Press, Totowa, NJ, pp109-123, 2009.
39. Knudsen ES and Knudsen KE: Tailoring to Rb: tumour suppressor status and therapeutic response. Nat Rev Cancer 8: 714-724, 2008.
40. Mattioli E, Vogiatzi P, Sun A, Abbadessa G, Angeloni G, D'Ugo D, Trani D, Gaughan JP, Vecchio FM, Cevenini G, Persiani R, Giordano A and Claudio PP: Immunohistochemical analysis of pRb2/p130, VEGF, EZH2, p53, p16(INK4A), p27(KIP1), p21(WAF1), Ki-67 expression patterns in gastric cancer. J Cell Physiol 210: 183-191, 2007.
41. Hu J, Liu S, Wang J, Luo X, Gao X, Xia X, Feng Y, Tao D, Wang G, Li X, Zhao J, DingH, Reed E, Li QQ and Gong J: Overexpression of the N-terminal end of the p55gamma regulatory subunit of phosphatidylinositol 3-kinase blocks cell cycle progression in gastric carcinoma cells. Int J Oncol 26: 1321-1327, 2005.
42. Yoo YD, Choi JY, Lee SJ, Kim JS, Min BR, Lee YI and Kang YK: TGF-beta-induced cell-cycle arrest through the p21 (WAF1/CIP1)-G1 cyclin/Cdks-p130 pathway in gastric-carcinoma cells. Int J Cancer 83: 512-517, 1999.
43. Songun I, van de Velde CJ, Hermans J, Pals ST, Verspaget HW, Vis AN, Menon AG, Litvinov SV and van Krieken JH: Expression of oncoproteins and the amount of eosinophilic and lymphocytic infiltrates can be used as prognostic factors in gastric cancer. Dutch Gastric Cancer Group (DGCG). Br J Cancer 74: 1783-1788, 1996.
44. Coppola D, Schreiber RH, Mora L, Dalton W and Karl RC: Significance of Fas and retinoblastoma protein expression during the progression of Barrett's metaplasia to adenocarcinoma. Ann Surg Oncol 6: 298-304, 1999.
45. Friend SH, Bernards R, Rogelj S, Weinberg RA, Rapaport JM, Albert DM and Dryja TP: A human DNA segment with properties of the gene that predisposes to retinoblastoma and osteosarcoma. Nature 323: 643-646, 1986.
46. Weinberg RA: The retinoblastoma protein and cell cycle control (Review). Cell 81: 323-330, 1995.
47. Chatterjee SJ, George B, Goebell PJ, Alavi-Tafreshi M, Shi SR, Fung YK, Jones PA, Cordon-Cardo C, Datar RH and Cote RJ: Hyperphosphorylation of pRb: a mechanism for RB tumour suppressor pathway inactivation in bladder cancer. J Pathol 203: 762-770, 2004.
48. Whyte P, Williamson NM and Harlow E: Cellular targets for transformation by the adenovirus E1A proteins. Cell 56: 67-75, 1989.
49. Bagchi S, Raychaudhuri P and Nevins JR: Adenovirus E1A proteins can dissociate heteromeric complexes involving the E2F transcription factor: a novel mechanism for E1A transactivation. Cell 62: 659-669, 1990.
50. Bandara LR and La Thangue B: Adenovirus E1a prevents the retinoblastoma gene product from complexing with a cellular transcription factor. Nature 351: 494-497, 1991.
51. Zur Hausen H: Papillomavirus infections, a major cause of human cancers (Review). Biochim Biophys Acta 1288: F55-F78, 1996.
52. Chellappan S, Kraus VB, Kroger B, Munger K, Howley PM, Phelps WC and Nevins JR: Adenovirus E1A, simian virus 40 tumor antigen, and human papillomavirus E7 protein share the capacity to disrupt the interaction between transcription factor E2F and the retinoblastoma gene product. Proc Natl Acad Sci USA 89: 4549-4553, 1992.
53. Knudsen ES and Wang JY: Differential regulation of retinoblastoma protein function by specific Cdk phosphorylation sites. J Biol Chem 271: 8313-8320, 1996.
54. Pardee AB: G1 events and regulation of cell proliferation. Science 246: 603-608, 1989.
55. Herrera RE, Sah VP, Williams BO, Mäkelä TP, Weinberg RA and Jacks T: Altered cell cycle kinetics, gene expression, and G1 restriction point regulation in Rb-deficient fibroblasts. Mol Cell Biol 16: 2402-2407, 1996.
56. Harbour JW, Luo RX, Dei Santi A, Postigo AA and Dean DC: Cdk phosphorylation triggers sequential intramolecular interactions that progressively block Rb functions as cells move through G1. Cell 98: 859-869, 1999.
57. Markaki EA, Tsopanomichalou M, Dimitriou H, Stiakaki E, Perdikoyanni C, Spandidos D and Kalmanti M: Mutations of retinoblastoma gene (Rb-1) as a prognostic factor in children with acute leukemia and neuroblastoma. Pediatr Hematol Oncol 18: 101-110, 2001.
58. Chim CS, Wong KY, Loong F, Lam WW and Srivastava G: Frequent epigenetic inactivation of Rb1 in addition to p15 and p16 in mantle cell and follicular lymphoma. Hum Pathol 38: 1849-1857, 2007.
59. Polsky D, Mastorides S, Kim D, Dudas M, Leon L, Leung D, Woodruff JM, Brennan MF, Osman I and Cordon-Cardo C: Altered patterns of RB expression define groups of soft tissue sarcoma patients with distinct biological and clinical behavior. Histopathol 21: 743-752, 2006.
60. Sherr CJ: Cancer cell cycles. Science 274: 1672-1677, 1996.
61. Mayhew CN, Carter SL, Fox SR, Sexton CR, Reed CA, Srinivasan SV, Liu X, Wikenheiser-Brokamp K, Boivin GP, Lee JS, Aronow BJ, Thorgeirsson SS and Knudsen ES: Rb loss abrogates cell cycle control and genome integrity to promote liver tumorigenesis. Gastroenterology 133: 976-984, 2007.
62. Amato A, Lentini L, Schillaci T, Iovino F and Di Leonardo A: Rnai mediated acute depletion of retinoblastoma protein (pRb) promotes aneuploidy in human primary cells via micronuclei formation. BMC Cell Biol 10: 79, 2009.
63. Arici DS, Tuncer E, Ozer H, Simek G and Koyuncu A: Expression of retinoblastoma and cyclin D1 in gastric carcinoma. Neoplasma 56: 63-67, 2009.
64. Kim JS, Pirnia F, Choi YH, Nguyen PM, Knepper B, Tsokos M, Schulte TW, Birrer MJ, Blagosklonny MV, Schaefer O, Mushinski JF and Trepel JB: Lovastatin induces apoptosis in a primitive neuroectodermal tumor cell line in association with RB down-regulation and loss of the G1 checkpoint. Oncogene 19: 6082-6090, 2000.
65. Tchernev G and Orfanos CE: Downregulation of cell cycle modulators p21, p27, p53, Rb and proapoptotic Bcl-2-related proteins Bax and Bak in cutaneous melanoma is associated with worse patient prognosis: preliminary findings. J Cutan Pathol 34: 247-256, 2007.
66. Souza RF and Spechler SJ: Concepts in the prevention of adenocarcinoma of the distal esophagus and proximal stomach (Review). CA Cancer J Clin 55: 334-351, 2005.
67. Spechler SJ: Clinical practice. Barrett's esophagus. N Engl J Med 346: 836-842, 2002.
68. Simpson DJ, Hibberts NA, McNicol AM, Clayton RN and Farrell WE: Loss of pRb expression in pituitary adenomas is associated with methylation of the RB1 CpG island. Cancer Res 60: 1211-1216, 2000.
69. Akin H, Yilmazbayhan D, Kiliçaslan Z, Dilege S, Dogan O, Toker A and Kalayci G: Clinical significance of P16INK4A and retinoblastoma proteins in non-small-cell lung carcinoma. Lung Cancer 38: 253-260, 2002.
70. Corsino P, Davis B, Law M, Chytil A, Forrester E, Nørgaard P, Teoh N and Law B: Tumors initiated by constitutive Cdk2 activation exhibit transforming growth factor beta resistance and acquire paracrine mitogenic stimulation during progression. Cancer Res 67: 3135-3144, 2007.
71. Kubota Y, Fujinami K, Uemura H, Dobashi Y, Miyamoto H, Iwasaki Y, Kitamura H and Shuin T: Retinoblastoma gene mutations in primary human prostate cancer. Prostate 27: 314-320, 1995.
72. Wikenheiser-Brokamp KA: Retinoblastoma regulatory pathway in lung cancer (Review). Curr Mol Med 6: 783-793, 2006. (Pubitemid 44725570)
73. Strohmeyer T, Reissmann P, Cordon-Cardo C, Hartmann M, Ackermann R and Slamon D: Correlation between retinoblastoma gene expression and differentiation in human testicular tumors. Proc Natl Acad Sci USA 88: 6662-6666, 1991.
74. Mack PC, Chi SG, Meyers FJ, Stewart SL, deVere White RW and Gumerlock PH: Increased RB1 abnormalities in human primary prostate cancer following combined androgen blockade. Prostate 34: 145-151, 1998.
75. Stirzaker C, Millar DS, Paul CL, Warnecke PM, Harrison J, Vincent PC, Frommer M and Clark SJ: Extensive DNA methylation spanning the Rb promoter in retinoblastoma tumors. Cancer Res 57: 2229-2237, 1997.
76. Lan J, Xiong YY, Lin YX, Wang BC, Gong LL, Xu HS and Guo GS: Helicobacter pylori infection generated gastric cancer through p53-Rb tumor-suppressor system mutation and telomerase reactivation. World J Gastroenterol 9: 54-58, 2003.
77. De Luca A, Baldi A, Russo P, Todisco A, Altucci L, Giardullo N, Pasquale L, Iaquinto S, D'Onofrio V, Parodi MC, Paggi MG and Iaquinto G: Coexpression of Helicobacter pylori's proteins CagA and HspB induces cell proliferation in AGS gastric epithelial cells, independently from the bacterial infection. Cancer Res 63: 6350-6356, 2003.
78. Choi HJ, Kim DY and Park JH: Induction of G1 and G2/M cell cycle arrests by the dietary compound 3,3′-diindolylmethane in HT-29 human colon cancer cells. BMC Gastroenterol 9: 39, 2009.
79. Guo J, Miao Y, Xiao B, Huan R, Jiang Z, Meng D and Wang Y: Differential expression of microRNA species in human gastric cancer versus non-tumorous tissues. J Gastroenterol Hepatol 24: 652-657, 2009.
80. Mayol X, Graña X, Baldi A, Sang N, Hu Q and Giordano A: Cloning of a new member of the retinoblastoma gene family (pRb2) which binds to the E1A transforming domain. Oncogene 8: 2561-2566, 1993.
81. Yeung RS, Bell DW, Testa JR, Mayol X, Baldi A, Graña X, Klinga-Levan K, Knudson AG and Giordano A: The retinoblastoma- related gene, RB2, maps to human chromosome 16q12 and rat chromosome 19. Oncogene 8: 3465-3468, 1993.
82. Mayol X, Garriga J and Graña X: G1 cyclin/CDK-independent phosphorylation and accumulation of p130 during the transition from G1 to G0 lead to its association with E2F-4. Oncogene 13: 237-244, 1996.
83. Cheng L, Rossi F, Fang W, Mori T and Cobrinik D: Cdk2- dependent phosphorylation and functional inactivation of the pRB-related p130 protein in pRB(-), p16INK4A(+) tumor cells. J Biol Chem 275: 30317-30325, 2000.
84. Calbó J, Parreño M, Sotillo E, Yong T, Mazo A, Garriga J and Grana X: G1 cyclin/cyclin-dependent kinase-coordinated phosphorylation of endogenous pocket proteins differentially regulates their interactions with E2F4 and E2F1 and gene expression. J Biol Chem 277: 50263-50274, 2002.
85. Litovchick L, Chestukhin A and DeCaprio JA: Glycogen synthase kinase 3 phosphorylates RBL2/p130 during quiescence. Mol Cell Biol 24: 8970-8980, 2004.
86. Mayol X, Garriga J and Graña X: Cell cycle-dependent phosphorylation of the retinoblastoma-related protein p130. Oncogene 11: 801-808, 1995.
87. Garriga J, Limón A, Mayol X, Rane SG, Albrecht JH, Reddy EP, Andrés V and Graña X: Differential regulation of the retino-blastoma family of proteins during cell proliferation and differentiation. Biochem J 333: 645-654, 1998.
88. Murphy N, Ring M, Heffron CC, Martin CM, McGuinness E, Sheils O and O'Leary JJ: Quantitation of CDC6 and MCM5 mRNA in cervical intraepithelial neoplasia and invasive squamous cell carcinoma of the cervix. Mod Pathol 18: 844-849, 2005.
89. Chen H, Huang Q, Dong J, Zhai DZ, Wang AD and Lan Q: Overexpression of CDC2/CyclinB1 in gliomas, and CDC2 depletion inhibits proliferation of human glioma cells in vitro and in vivo. BMC Cancer 8: 29, 2008.
90. Aaltonen K, Ahlin C, Amini RM, Salonen L, Fjällskog ML, Heikkilä P, Nevanlinna H and Blomqvist C: Reliability of cyclin A assessment on tissue microarrays in breast cancer compared to conventional histological slides. Br J Cancer 94: 1697-1702, 2006.
91. Li Q, Sakurai Y, Ryu T, Azuma K, Yoshimura K, Yamanouchi Y, Ikehara S and Kawamoto K: Expression of Rb2/p130 protein correlates with the degree of malignancy in gliomas. Brain Tumor Pathol 21: 121-125, 2004.
92. Claudio PP, Caputi M and Giordano A: The RB2/p130 gene: the latest weapon in the war against lung cancer? (Review). Clin Cancer Res 6: 754-764, 2000.
93. Claudio PP, Howard CM, Pacilio C, Cinti C, Romano G, Minimo C, Maraldi NM, Minna JD, Gelbert L, Leoncini L, Tosi GM, Hicheli P, Caputi M, Giordano GG and Giordano A: Mutations in the retinoblastoma-related gene RB2/p130 in lung tumors and suppression of tumor growth in vivo by retrovirus-mediated gene transfer. Cancer Res 60: 372-382, 2000.
94. De Falco G, Leucci E, Lenze D, Piccaluga PP, Claudio PP, Onnis A, Cerino G, Nyagol J, Mwanda W, Bellan C, Hummel M, Pileri S, Tosi P, Stein H, Giordano A and Leoncini L: Gene-expression analysis identifies novel RBL2/p130 target genes in endemic Burkitt lymphoma cell lines and primary tumors. Blood 110: 1301-1307, 2007.
95. Milde-Langosch K, Goemann C, Methner C, Rieck G, Bamberger AM and Löning T: Expression of Rb2/p130 in breast and endometrial cancer: correlations with hormone receptor status. Br J Cancer 85: 546-551, 2001. (Pubitemid 32808279)
96. Cinti C, Macaluso M and Giordano A: Tumor-specific exon 1 mutations could be the 'hit event' predisposing Rb2/p130 gene to epigenetic silencing in lung cancer. Oncogene 24: 5821-5826, 2005.
97. Cinti C, Claudio PP, Howard CM, Neri LM, Fu Y, Leoncini L, Tosi GM, Maraldi NM and Giordano A: Genetic alterations disrupting the nuclear localization of the retinoblastoma-related gene RB2/p130 in human tumor cell lines and primary tumors. Cancer Res 60: 383-389, 2000.
98. Vuocolo S, Purev E, Zhang D, Bartek J, Hansen K, Soprano DR and Soprano KJ: Protein phosphatase 2A associates with Rb2/ p130 and mediates retinoic acid-induced growth suppression of ovarian carcinoma cells. J Biol Chem 278: 41881-4189, 2003.
99. Howard CM, Claudio PP, Gallia GL, Gordon J, Giordano GG, Hauck WW, Khalili K and Giordano A: Retinoblastoma-related protein pRb2/p130 and suppression of tumor growth in vivo. J Natl Cancer Inst 90: 1451-1460, 1998.
100. Lazzi S, Bellan C, De Falco G, Cinti C, Ferrari F, Nyongo A, Claudio PP, Tosi GM, Vatti R, Gloghini A, Carbone A, Giordano A, Leoncini L and Tosi P: Expression of RB2/p130 tumor-suppressor gene in AIDS-related non-Hodgkin's lymphomas: implications for disease pathogenesis. Hum Pathol 33: 723-731, 2002.
101. Huynh H: Overexpression of tumour suppressor retinoblastoma 2 protein (pRb2/p130) in hepatocellular carcinoma. Carcinogenesis 25: 1485-1494, 2004.
102. Maraldi NM, Giordano A, Manzoli L, Falconi M, Pol AD and Cinti C: Genetic alterations at the nuclear localization signal of the rb2/p130 gene occur in lymphoid tumor but not in osteosarcoma cell lines. Adv Enzyme Regul 41: 31-55, 2001. (Pubitemid 32520314)
103. Popov B, Chang LS and Serikov V: Cell cycle-related transformation of the E2F4-p130 repressor complex. Biochem Biophys Res Commun 33: 762-769, 2005.
104. Ewen ME, Xing YG, Lawrence JB and Livingston DM: Molecular cloning, chromosomal mapping, and expression of the cDNA for p107, a retinoblastoma gene product-related protein. Cell 66: 1155-1164, 1991.
105. Ginsberg D, Vairo G, Chittenden T, Xiao ZX, Xu G, Wydner KL, DeCaprio JA, Lawrence JB and Livingston DM: E2F-4, a new member of the E2F transcription factor family, interacts with p107. Genes Dev 8: 2665-2679, 1994.
106. Beijersbergen RL, Kerkhoven RM, Zhu L, Carlée L, Voorhoeve PM and Bernards R: E2F-4, a new member of the E2F gene family, has oncogenic activity and associates with p107 in vivo. Genes Dev 8: 2680-2690, 1994.
107. Dyson N: The regulation of E2F by pRB-family proteins (Review). Genes Dev 12: 2245-2262, 1998.
108. Lipinski MM and Jacks T: The retinoblastoma gene family in differentiation and development (Review). Oncogene 18: 7873-7882, 1999.
109. Ewen ME: The cell cycle and the retinoblastoma protein family (Review). Cancer Metastasis Rev 13: 45-66, 1994.
110. Lee MH, Williams BO, Mulligan G, Mukai S, Bronson RT, Dyson N, Harlow E and Jacks T: Targeted disruption of p107: functional overlap between p107 and Rb. Genes Dev 10: 1621-1623, 1996.
111. Cobrinik D, Lee MH, Hannon G, Mulligan G, Bronson RT, Dyson N, Harlow E, Beach D, Weinberg RA and Jacks T: Shared role of the pRB-related p130 and p107 proteins in limb development. Genes Dev 10: 1633-1644, 1996.
112. Xiao ZX, Ginsberg D, Ewen M and Livingston DM: Regulation of the retinoblastoma protein-related protein p107 by G1 cyclin-associated kinases. Proc Natl Acad Sci USA 93: 4633-4637, 1996.
113. Castaño E, Kleyner Y and Dynlacht BD: Dual cyclin-binding domains are required for p107 to function as a kinase inhibitor. Mol Cell Biol 18: 5380-5391, 1998.
114. Bookstein R, Shew JY, Chen PL, Scully P and Lee WH: Suppression of tumorigenicity of human prostate carcinoma cells by replacing a mutated RB gene. Science 247: 712-715, 1990. (Pubitemid 120031355)
115. Wu F, Li JQ, Miki H, Nishioka M, Fujita J, Ohmori M, Imaida K and Kuriyama S: p107 Expression in colorectal tumours rises during carcinogenesis and falls during invasion. Eur J Cancer 38: 1838-1848, 2002.
116. Lara MF, García-Escudero R, Ruiz S, Santos M, Moral M, Martínez-Cruz AB, Segrelles C, Lorz C and Paramio JM: Gene profiling approaches help to define the specific functions of retinoblastoma family in epidermis. Mol Carcinog 47: 209-221, 2008.
117. Santos M, Ruiz S, Lara MF, et al: Susceptibility of prb-deficient epidermis to chemical skin carcinogenesis is dependent on the p107 allele dosage. Mol Carcinog 47: 815-821, 2008.
118. Ruiz S, Santos M, Segrelles C, et al: Unique and overlapping functions of pRb and p107 in the control of proliferation and differentiation in epidermis. Development 131: 2737-2748, 2004.
119. Song XC, Fu G, Yang X, Jiang Z, Wang Y and Zhou GW: Protein expression profiling of breast cancer cells by dissociable antibody microarray (DAMA) staining. Mol Cell Proteomics 7: 163-169, 2008.
120. Lehmann BD, Brooks AM, Paine MS, Chappell WH, McCubrey JA and Terrian DM: Distinct roles for p107 and p130 in Rb-independent cellular senescence. Cell Cycle 7: 1262-1268, 2008.
121. Dannenberg JH, Schuijff L, Dekker M, van der Valk M and te Riele H: Tissue-specific tumor suppressor activity of retinoblastoma gene homologs p107 and p130. Genes Dev 18: 2952-2962, 2004.
122. Wang RH, Fang M and Xue SB: Changes of intracellular calcium, calmodulin in normal and tumor cells traggered by staurosporine. Shi Yan Sheng Wu Xue Bao 29: 133-139, 1996.
123. Dyson N: The regulation of E2F by pRB-family proteins. Genes Dev 12: 2245-2262, 1998.
124. Kennedy BK, Liu OW, Dick FA, Dyson N, Harlow E and Vidal M: Histone deacetylase-dependent transcriptional repression by pRb in yeast occurs independently of interaction through the lxcxe binding cleft. Proc Natl Acad Sci USA 98: 8720-8725, 2001.
125. Bouzahzah B, Fu M, Iavarone A, Factor VM, Thorgeirsson SS and Pestell RG: Transforming growth factor-beta1 recruits histone deacetylase 1 to a p130 repressor complex in transgenic mice in vivo. Cancer Res 60: 4531-4537, 2000.
126. Gu W, Schneider JW, Condorelli G, Kaushal S, Mahdavi V and Nadal-Ginard B: Interaction of myogenic factors and the retinoblastoma protein mediates muscle cell commitment and differentiation. Cell 72: 309-324, 1993.
127. Wang S, Ghosh RN and Chellappan SP: Raf-1 physically interacts with Rb and regulates its function: a link between mitogenic signaling and cell cycle regulation. Mol Cell Biol 18: 7487-7498, 1998.
128. Jiao W, Lin HM, Datta J, Braunschweig T, Chung JY, Hewitt SM and Rane SG: Aberrant nucleocytoplasmic localization of the retinoblastoma tumor suppressor protein in human cancer correlates with moderate/poor tumor differentiation. Oncogene 27: 3156-3164, 2008.
129. Manjarrez ME, Ocadiz R, Valle L, Pacheco C, Marroquin A, De la Torre C, Selman M and Gariglio P: Detection of human papillomavirus and relevant tumor suppressors and oncoproteins in laryngeal tumors. Clin Cancer Res 12: 6946-6951, 2006.
130. Jun H, Gemma A, Hosoya Y, Matsuda K, Nara M, Hosomi Y, Okano T, Kurimoto F, Seike M, Takenaka K, Yoshimura A, Toyota M and Kudoh S: Reduced transcription of the RB2/ p130 gene in human lung cancer. Mol Carcinog 38: 124-129, 2003.
131. Russo G, Claudio PP, Fu Y, Stiegler P, Yu Z, Macaluso M and Giordano A: pRB2/p130 target genes in non-small lung cancer cells identified by microarray analysis. Oncogene 22: 6959-6969, 2003.
132. Ito Y, Yoshida H, Tomoda C, Uruno T, Takamura Y, Miya A, Kobayashi K, Matsuzuka F, Kuma K and Miyauchi A: Decreased expression of p107 is correlated with anaplastic transformation in papillary carcinoma of the thyroid. Anticancer Res 23: 4121-4125, 2003.